- 24/01/2010
- 111
- 76
- 48
Eu concordo com o Muilok acho que o peso e altura influenciam bastante mas tem uma coisa que eu não consigo definir o que é mas vou tentar explicar, tenho um amigo que experimentou junto comigo, ele tem um metabolismo muito rapido, ao contrario de mim, ele já começou a sentir as sensações quando estava ainda comendo, derrepente entrou numa viagem louca, ficou cheio de energia e não parava de falar, mas a loucura dele passou rapido cerca de quatro horas e eu que ingeri mais tive uma viagem mais branda que durou mais tempo!!!
Dahua acho que dá pra fazer uma tabela muito assim como base, vai ser muito questionada, pois cada um é cada um, não tem jeito, mas se precisar de alguma ajuda pode contar com a gente!!!
Abraço a todos
'' Under supportive conditions, 20 and 30 mg/70 kg psilocybin occasioned mystical-type experiences having persisting positive effects on attitudes, mood, and behavior.''
Fonte: Psychopharmacology (Berl). 2011 Dec;218(4):649-65. Epub 2011 Jun 15.
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects.
Griffiths RR, Johnson MW, Richards WA, Richards BD, McCann U, Jesse R.
Source
Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD 21224-6823, USA. rgriff@jhmi.edu
Abstract
RATIONALE:
This dose-effect study extends previous observations showing that psilocybin can occasion mystical-type experiences having persisting positive effects on attitudes, mood, and behavior.
OBJECTIVES:
This double-blind study evaluated psilocybin (0, 5, 10, 20, 30 mg/70 kg, p.o.) administered under supportive conditions.
METHODS:
Participants were 18 adults (17 hallucinogen-naïve). Five 8-h sessions were conducted individually for each participant at 1-month intervals. Participants were randomized to receive the four active doses in either ascending or descending order (nine participants each). Placebo was scheduled quasi-randomly. During sessions, volunteers used eyeshades and were instructed to direct their attention inward. Volunteers completed questionnaires assessing effects immediately after and 1 month after each session, and at 14 months follow-up.
RESULTS:
Psilocybin produced acute perceptual and subjective effects including, at 20 and/or 30 mg/70 kg, extreme anxiety/fear (39% of volunteers) and/or mystical-type experience (72% of volunteers). One month after sessions at the two highest doses, volunteers rated the psilocybin experience as having substantial personal and spiritual significance, and attributed to the experience sustained positive changes in attitudes, mood, and behavior, with the ascending dose sequence showing greater positive effects. At 14 months, ratings were undiminished and were consistent with changes rated by community observers. Both the acute and persisting effects of psilocybin were generally a monotonically increasing function of dose, with the lowest dose showing significant effects.
CONCLUSIONS:
Under supportive conditions, 20 and 30 mg/70 kg psilocybin occasioned mystical-type experiences having persisting positive effects on attitudes, mood, and behavior. Implications for therapeutic trials are discussed
http://www.springerlink.com/content/u464377x433p5957/